New Data Validating the First AI-Based Biomarker to Stratify Risk of Metastasis in Radical Prostatectomy Patients with Biochemical Recurrence
Artera, the developer of multimodal artificial intelligence-based prognostic and predictive cancer tests, announced the valid [...]
Doctors Explain What Prostate Cancer Screenings Involve
If you've never had a prostate cancer screening, you may worry that it will be embarrassing and uncomfortable. Doctors say th [...]
ArteraAI and Movember Announce New Relationship
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, today anno [...]
ArteraAI Prostate Test Included in NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Prostate Cancer have included the ArteraAI [...]
ArteraAI Included in the 2024 NCCN Guidelines® for Prostate Cancer
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
Here’s how AI will drive health care to meet consumer expectations
The rapid transformation of the health care landscape is undeniable. It is marked not only by groundbreaking technologies and [...]
Exclusive: ArteraAI nabs $20M to take personalized cancer care global
ArteraAI, a developer of AI tests to personalize therapy for cancer patients, raised $20 million in additional funding, CEO A [...]
ArteraAI Secures $20 Million in Funding to Further Personalize Cancer Therapy With Multimodal AI
ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tests, announced [...]
Prostate cancer myths and common misconceptions from an oncologist amid high-profile cases
Amid a flurry of high-profile prostate cancer announcements, doctors are weighing in to debunk common myths about the disease [...]